MPLN.Multiplan CORP
DEF: Claritev Reports Strong 2025 Performance, Eyes Growth
Sentiment:
Definitive Proxy Statement
Claritev Corporation's definitive proxy statement highlights a return to positive revenue growth, improved Adjusted EBITDA, and strengthened free cash flow in 2025, alongside strategic expansion and digital transformation efforts.
Capital raiseOn November 12, 2025, Claritev entered into an Underwriting Agreement with certain affiliates of H&F (Selling Stockholders) for the offer and sale of 1,500,000 shares of Class A common stock at $51.50 per share.The Selling Stockholders granted underwriters a 30-day option to purchase up to an additional 225,000 shares.Claritev did not sell any shares or receive any proceeds from this offering.Claritev paid certain registration expenses in connection with the offering, exclusive of underwriting discounts and commissions.
Better than expectedReturned to positive revenue growth in 2025, with actual revenue of $965.4 million exceeding the target of $915.0 million.Improved Adjusted EBITDA in 2025, exceeding the target of $574.9 million with actual Adjusted EBITDA of $602.6 million.Total stockholder return for 2025 was 189%, significantly outperforming the S&P Composite 1500 Health Care Technology Index.
Summary
- Claritev Corporation achieved positive revenue growth, improved Adjusted EBITDA, and strengthened free cash flow in 2025, exceeding initial outlooks.
- The company expanded into new vertical markets and delivered over $67 million of new Annual Contract Value.
- A multi-year digital transformation effort was launched, including moving applications and technology infrastructure to the cloud.
- Claritev processed a record $179.8 billion in medical charges in 2025, identifying $25.0 billion of potential medical cost savings.
- The company's total stockholder return (TSR) for 2025 was 189%.
- For 2026, Claritev will reimplement performance stock units (PSUs) for executive officers, with 25% of long-term incentive awards based on unlevered free cash flow performance.
- Stockholders are asked to approve an amendment to the 2020 Omnibus Incentive Plan to increase shares available for grant by an additional 2,375,000 shares, bringing the total to 7,771,250 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing positively due to the strong financial performance in 2025, exceeding expectations for revenue and Adjusted EBITDA, and significant TSR outperformance against its peer index. However, negative free cash flow and historical net losses due to impairments temper the overall sentiment.
Positives
- Returned to positive revenue growth in 2025, with actual revenue of $965.4 million exceeding the target of $915.0 million.
- Improved Adjusted EBITDA in 2025, reaching $602.6 million, which was above the target of $574.9 million.
- Strengthened free cash flow in 2025 compared to the initial outlook.
- Expanded into new vertical markets and signed the first international customer.
- Delivered over $67 million of new Annual Contract Value.
- Launched a multi-year digital transformation effort to enhance operational rigor and innovation.
- Processed a record $179.8 billion in medical charges, identifying $25.0 billion of potential medical cost savings in 2025.
- Achieved a total stockholder return (TSR) of 189% for 2025, significantly outperforming the S&P Composite 1500 Health Care Technology Index.
- The Executive Leadership Team (ELT) voluntarily reduced their 2025 bonus payouts from 125.8% to 110% of target to allow for greater funding of the bonus pool for non-ELT employees.
- Reimplementation of performance stock units in 2026 strengthens the pay-for-performance philosophy for executive compensation.
Negatives
- Reported a net loss of $284.282 million in 2025, despite significant improvement from the prior year.
- Free cash flow remained negative at $(12.277) million in 2025, a slight decrease from $(10.507) million in 2024.
- The proposed Share Reserve Increase for the 2020 Omnibus Incentive Plan has a dilutive effect of 9.97%, with total potential dilution, including outstanding awards, at 28.81%.
- Historical Total Stockholder Return (TSR) was negative in 2021, 2022, and 2024, and lagged well behind the S&P Composite 1500 Health Care Technology Index in those years.
- Net income declined significantly from 2023 to 2024 due to a $1.5 billion loss on impairment of goodwill and intangible assets.
Risks
- Cybersecurity and artificial intelligence risks are identified as key risk areas for operations.
- The company faces risks related to rising costs, regulatory complexity, and system fragmentation within the healthcare ecosystem.
- Corporate transactions or unusual events affecting common stock could result in substantial dilution or enlargement of rights for participants in equity plans.
- Equity awards are subject to forfeiture upon termination of employment if vesting restrictions are not satisfied.
- Awards are subject to reduction, cancellation, forfeiture, or recoupment if a participant receives an excess amount or engages in detrimental activity.
Future Outlook
Claritev is entering 'The Way Up' phase, focusing on disciplined growth, expanding its core business, and making intentional investments in technology, product innovation, and AI to enhance transparency and affordability in healthcare. The company anticipates continued positive growth and transformation, supported by the reintroduction of performance stock units in 2026 for executive compensation, tied to unlevered free cash flow. The proposed increase in the equity incentive plan shares is intended to meet forecasted needs for attracting and retaining talent over the next 12 to 24 months.
Management Comments
- "We committed to building Vision 2030 – not Vision 20 Minutes. That long-term mindset continues to guide our strategy and the oversight of our Board."
- "In 2025, we completed what we called the Year of the Turn. We returned to positive revenue growth, improved Adjusted EBITDA, and strengthened free cash flow compared to our initial outlook."
- "Today, we are moving into the next phase: The Way Up. The Way Up represents disciplined growth."
- "Artificial intelligence is an important extension of those advantages. We are prioritizing AI where it drives measurable outcomes – revenue growth, cost reduction, and risk mitigation – embedded directly into real-world healthcare workflows."
- "The Company’s Executive Leadership Team (ELT) asked the Compensation Committee to use its negative discretion and decrease bonus payouts to 110% of the overall target for ELT members to allow for greater funding of the bonus pool to recognize other non-ELT employees."
Industry Context
StockSavvy.ai notes that Claritev operates in the highly dynamic healthcare technology sector, leveraging data and AI to address industry-wide challenges of transparency, affordability, and quality. Its focus on processing medical charges and identifying cost savings aligns with the increasing pressure on healthcare providers and payers to optimize expenses and demonstrate value. The expansion into new vertical markets and international territories indicates a strategy to diversify revenue streams and capitalize on global demand for healthcare efficiency solutions, a trend observed across the industry as digital transformation accelerates.
Comparison to Industry Standards
- Claritev's 2025 Total Stockholder Return (TSR) of 189% significantly outperformed the S&P Composite 1500 Health Care Technology Index (HCT Index) TSR of 69.70% for the same period.
- In contrast, Claritev's TSR lagged the HCT Index in 2021 (55.40% vs. 117.60%), 2022 (14.40% vs. 100.00%), and 2024 (4.60% vs. 79.70%), indicating variability in past performance relative to the broader sector.
- The company's adjusted EBITDA of $602.6 million in 2025, while an improvement, should be benchmarked against peers like Veeva Systems Inc. or Evolent Health, Inc. to assess relative operational efficiency within the healthcare technology space.
- The proposed equity plan dilution of 9.97% for the Share Reserve Increase and 28.81% total potential dilution should be compared to typical dilution rates for growth-oriented tech companies, which often range from 10-20% over a few years, to determine if it is within acceptable industry norms for talent retention and motivation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | P. Hunter Philbrick | Jason L. Kap | April 2025 | Mr. Philbrick did not stand for re-election. |
| Chair of the Compensation Committee | P. Hunter Philbrick | Julie D. Klapstein | Following 2025 Annual Meeting | Mr. Philbrick's departure. |
| Executive Vice President and Chief Digital Officer | Senior Vice President and Chief Information Officer | Michael C. Kim | February 2025 | Promotion. |
| Chief Strategy Officer | Senior Vice President, Corporate Affairs & Strategy | William B. Mintz | September 2025 | Promotion. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Mr. Kap elected as a Class II director, succeeding P. Hunter Philbrick. | April 2025 | Enhances board expertise with technology industry experience. |
| Committee Leadership | Ms. Klapstein assumed the role of chair of the Compensation Committee. | Following 2025 Annual Meeting | Ensures continuity and experienced leadership for executive compensation oversight. |
| Committee Membership | Mr. Clarke and Dr. Harris joined the Nominating and Corporate Governance Committee as members. | Following 2025 Annual Meeting | Adds expertise in cybersecurity, risk management, and healthcare to director nomination and governance oversight. |
| Committee Membership | Mr. Kap joined the Compensation Committee and the Risk Committee. | Following 2025 Annual Meeting | Brings technology and pricing strategy expertise to compensation and risk oversight. |
| Director Retirement Policy Waiver | Board waived the mandatory retirement age of 75 for Mr. Richard A. Clarke. | 2026 | Retains Mr. Clarke's extensive knowledge in cybersecurity, AI, and security risk management, which are key to the company's operations. |
| Lead Independent Director Tenure Policy Waiver | Board waived the five-consecutive-year limit for Mr. Allen R. Thorpe to serve as Lead Director. | 2026 | Maintains experienced leadership and continuity in the Lead Director role, strengthening governance structure. |
| Executive Severance Protections | Extended the post-change in control protection period for executives from one year to two years. | March 2026 | Aligns executive change in control protections with market standards, potentially aiding executive retention during M&A scenarios. |
| Equity Incentive Plan Amendment | Proposed amendment to increase shares available for grant under the 2020 Omnibus Incentive Plan by 2,375,000 shares. | Upon stockholder approval | Critical for attracting, motivating, and retaining qualified personnel and aligning interests with stockholders, but will result in dilution. |
Legal Proceedings
- Sponsor and H&F have been involved in certain legal matters for which they are entitled to advancement of expenses and indemnification from Claritev under the terms of the Investor Rights Agreement.
Related Party Transactions
- Claritev is party to an Investor Rights Agreement with Churchill Sponsor III, LLC (Sponsor), Polaris Investment Holdings, L.P. (Holdings), Hellman & Friedman Capital Partners VIII, L.P. (H&F), The Public Investment Fund of the Kingdom of Saudi Arabia, and certain other parties, which provides for registration rights and indemnification rights.
- On November 12, 2025, Claritev entered into an Underwriting Agreement with certain affiliates of H&F (Selling Stockholders) for the offer and sale of 1,500,000 shares of Class A common stock at $51.50 per share. Claritev did not sell any shares or receive proceeds but paid certain registration expenses.
- Mr. Philbrick, former Chair of the Compensation Committee, is a Partner at the parent company of H&F, but did not have a material interest in the transactions.
Stakeholder Impact
- Shareholders: Potential for increased value through strategic growth and cost savings, but also dilution from the proposed equity incentive plan share increase. Will vote on key corporate governance matters.
- Employees: Enhanced bonus pool for non-ELT employees due to ELT's negative discretion on bonuses. Continued equity incentive awards for attraction and retention. Changes to 401(k) vesting schedule (improved for new employees, potentially less for long-term).
- Customers: Benefit from improved transparency, affordability, and quality in healthcare through Claritev's tech-enabled solutions and identified cost savings.
- Suppliers/Partners: Continued engagement in the healthcare ecosystem, potentially expanding with Claritev's growth into new vertical markets.
- Creditors: Financial performance (revenue, Adjusted EBITDA) and free cash flow improvements could positively impact creditworthiness.
Next Steps
- Annual Meeting of Stockholders on April 29, 2026, to vote on director elections, ratification of the accounting firm, executive compensation, and the amendment to the 2020 Omnibus Incentive Plan.
- Implementation of the 2026 executive compensation program, including performance stock units based on unlevered free cash flow performance.
- Release of the 2025 Corporate Responsibility Report in the third quarter of 2026.
- Continued execution of the 'The Way Up' strategy, focusing on disciplined growth and investment in technology, product innovation, and AI.
- Hiring additional employees to support commercialization efforts and business growth.
Key Dates
| Date | Description |
|---|---|
| 1980-01-01 | Claritev Corporation founded. |
| 2020-07-12 | Date of the Investor Rights Agreement. |
| 2020-10-13 | Date of Schedule 13D filed by H&F Holders. |
| 2021-01-01 | Start of fiscal year for which Mr. Tabak's compensation is reported. |
| 2021-06-23 | Grant date for some stock options held by Mr. Kim and Mr. White. |
| 2022-01-01 | Start of fiscal year for which Mr. White's compensation is reported. |
| 2022-01-31 | Mr. Mark Tabak served as CEO until this date. |
| 2022-02-01 | Mr. Dale White appointed CEO. |
| 2022-02-11 | Date of Schedule 13G/A filed by GIC Investor. |
| 2022-02-18 | Grant date for some stock options held by Mr. White. |
| 2022-03-01 | Grant date for some stock options and restricted stock units held by Mr. Kim and Mr. White. |
| 2023-01-01 | Start of fiscal year for which Mr. White's compensation is reported. |
| 2023-06-23 | Mr. John M. Prince joined the Board. |
| 2023-12-28 | Date of employment agreement with Mr. Dalton. |
| 2024-01-01 | Start of fiscal year for which Mr. Dalton's and Mr. White's compensation is reported. |
| 2024-02-12 | Date of Schedule 13G filed by The Public Investment Fund of the Kingdom of Saudi Arabia. |
| 2024-02-15 | Date of offer letter with Mr. Hogge. |
| 2024-02-26 | Date of filing Annual Report on Form 10-K for fiscal year 2025. |
| 2024-03-01 | Mr. Travis S. Dalton became President and CEO. Dalton Start Date for equity grants. |
| 2024-03-02 | Mr. Dale White served as Executive Chair until this date. |
| 2024-08-01 | Mr. Douglas M. Garis commenced employment. Garis Start Date for equity grants. |
| 2024-09-26 | Date of offer letter with Ms. Misencik. |
| 2024-10-14 | Ms. Tiffani D. Misencik commenced employment. |
| 2024-12-01 | Mr. Travis S. Dalton appointed Chair of the Board. |
| 2025-01-01 | Mr. Dale White served as Strategic Advisor to the Company from this date. |
| 2025-02-07 | Date of Schedule 13G/A filed by Ares Management Corporation. |
| 2025-02-27 | Company entered into severance letter agreements with Messrs. Hogge, Kim, and Ms. Misencik. Company amended employment agreements with Messrs. Dalton and Garis. |
| 2025-02-28 | Mr. Dalton acknowledged his 2025 long-term incentive grant and his employment agreement was amended. |
| 2025-03-01 | Grant date for 2025 long-term incentive awards to named executive officers. |
| 2025-04-01 | Mr. Jason Kap joined the Board. |
| 2025-04-29 | Effective date of increased committee retainers for non-employee directors. |
| 2025-08-24 | Ms. Klapstein joined the board of Omada Health. |
| 2025-09-01 | Mr. William B. Mintz appointed Chief Strategy Officer. |
| 2025-11-12 | Claritev entered into an Underwriting Agreement with certain affiliates of H&F for an offering of 1,500,000 shares. |
| 2025-11-14 | Closing date of the offering by Selling Stockholders. |
| 2025-12-31 | End of fiscal year 2025. Mr. Dale White's service as Strategic Advisor ended. |
| 2026-01-01 | Pay Governance formally replaced Korn Ferry as independent compensation consultant. |
| 2026-02-01 | Market adjustments to compensation of certain named executive officers made. |
| 2026-02-17 | Date of Schedule 13G/A filed by Arini Capital Management Limited. |
| 2026-03-06 | Record date for determining stockholders entitled to vote at the Annual Meeting. Date for share ownership information. |
| 2026-03-16 | Fair market value of common stock was $17.60 per share. |
| 2026-03-19 | Board of Directors approved the Amendment to the 2020 Omnibus Incentive Plan, subject to stockholder approval. |
| 2026-03-20 | Proxy statement and accompanying proxy card first made available. |
| 2026-03-31 | Company further amended employment agreements and severance letters to extend Post CiC Period to two years. |
| 2026-04-28 | Deadline for internet/telephone proxy voting. |
| 2026-04-29 | Date of the Annual Meeting of Stockholders. |
| 2026-07-01 | Anticipated release of the 2025 Corporate Responsibility Report in the third quarter of 2026. |
| 2026-11-20 | Deadline for stockholder proposals for inclusion in 2027 proxy statement. |
| 2026-12-30 | Earliest date for other proposals/nominees to be presented at 2027 Annual Meeting. |
| 2027-01-29 | Latest date for other proposals/nominees to be presented at 2027 Annual Meeting. |
| 2030-07-12 | No awards may be granted under the 2020 Omnibus Incentive Plan after this date. |
Recommendation
holdClaritev demonstrated strong operational and financial improvements in 2025, exceeding revenue and Adjusted EBITDA targets and delivering exceptional TSR. The strategic focus on AI, digital transformation, and market expansion is promising. However, the company still reported a net loss and negative free cash flow in 2025, and faces significant dilution from the proposed equity plan. While the turnaround is positive, a 'hold' recommendation is prudent to observe sustained profitability and positive free cash flow generation, and to assess the long-term impact of the dilution and strategic investments.
Keywords
Healthcare technology, Data analytics, AI, Healthcare transparency, Cost savings, SEC filing, Proxy statement, Corporate governance, Executive compensation, Equity incentive plan, Shareholder meeting, Claritev
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.